Next |
home / stock / apto / apto message board
Subject | By | Source | When |
---|---|---|---|
A nice short read on a PROTAC approach | dcaf7 | investorshub | 05/01/2023 12:22:38 AM |
Its not about revenue. | Tartiaboy | investorshub | 04/27/2023 7:20:11 PM |
The stock has dropped from the .60 area | Zeppo | investorshub | 04/25/2023 2:14:15 PM |
AML news. | dcaf7 | investorshub | 04/21/2023 5:09:01 PM |
TP53 rules. | Tartiaboy | investorshub | 04/20/2023 12:34:17 PM |
Precipitation in stomach rules. | dcaf7 | investorshub | 04/19/2023 11:35:52 PM |
It is what it is. Another option. | Tartiaboy | investorshub | 04/19/2023 9:23:53 PM |
Now they want you to vote for reverse | dcaf7 | investorshub | 04/19/2023 7:31:48 PM |
Good day for biotech tomorrow? | dcaf7 | investorshub | 04/16/2023 9:28:41 PM |
Thank you | Wolverine3 | investorshub | 04/14/2023 10:46:46 PM |
There is a chance but you need a | dcaf7 | investorshub | 04/14/2023 10:19:10 PM |
Ok, thanks. How about the possibility to displace | Wolverine3 | investorshub | 04/14/2023 9:04:33 PM |
Chance to be used after Gilteritinib? Sure. It | dcaf7 | investorshub | 04/14/2023 8:25:10 PM |
Decaf, do you think TUSP really has a | Wolverine3 | investorshub | 04/14/2023 4:46:46 PM |
Decaf, sounds like youre getting a bit more | spiderman3600 | investorshub | 04/14/2023 3:23:18 PM |
In addition, on Slide 12 you can see | dcaf7 | investorshub | 04/14/2023 2:17:41 PM |
A new redesigned Corporate presentation is available. | dcaf7 | investorshub | 04/14/2023 1:49:54 PM |
It was accelerated approval. Doesn't count much. But | dcaf7 | investorshub | 04/10/2023 6:44:09 PM |
Pirtobrutinib was approved for MCL in January. | Tartiaboy | investorshub | 04/10/2023 5:35:47 PM |
Possible reason for Zilo phase 3 trial termination? | dcaf7 | investorshub | 04/07/2023 1:22:22 PM |
News, Short Squeeze, Breakout and More Instantly...
Aptose Biosciences Inc. Company Name:
APTO Stock Symbol:
NASDAQ Market:
Aptose Biosciences Inc. Website:
Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AML Tuspetinib Continues Broad Activity Across Mutations with Excellent Safety Profile Luxeptinib G3 Formulation Achieves Desired Levels and Positions for Future Trials Conference Call ...
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...
SAN DIEGO and TORONTO, March 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical- stage precision oncology c...